SCHEMBL3340569

SCHEMBL3340569

C=CCOc1ccc(/C(N)=N/O)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 6/20 0.40
CA12 O43570 4/20 0.38
CA1 P00915 4/20 0.38
CA9 Q16790 4/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340572 1.00 ALDH1A1 (0.49) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL3343017 0.78 GAA (0.40) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL3343021 0.78 GAA (0.40) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL8875743 0.78 GAA (0.46) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL3340475 0.75 GAA (0.68) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL3340477 0.75 GAA (0.68) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL30826239 0.74 SMN1; SMN2 (0.49) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL4834529 0.74 BLM (0.47) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL3340573 0.74 MEN1 (0.41) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL20382459 0.73 HPGD (0.52) ALDH1A1MAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 ALDH1A1 1246/4885MAPT 4318/4885LMNA 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.